Carmeda^® BioActive Surface*

The Gold Standard in Biosurfaces for Extracorporeal Circuits

Carmeda^® BioActive Surface is an important component of many cardiovascular surgery teams' strategies to minimize the deleterious effects of cardiopulmonary bypass, providing these endothelial-like characteristics:

Heparin

• Non-leaching heparin molecules are covalently bonded into the surface using an End Point Attached method.
• The End Point Attached method assures that the heparin active binding sites are properly oriented to remain free to participate in biological reactions, similar to the orientation of heparan sulfate molecules naturally found on the vascular endothelium.
• A high degree of bioactivity is consistently delivered due to the unique Carmeda^® BioActive Surface chemistry and its sophisticated manufacturing process.

Negative charge

• Heparin in Carmeda^® BioActive Surface is naturally negatively charged. The vascular endothelium is also negatively charged.

Hydrophilicity

• Hydrophilic priming layer is strongly bonded to the artificial surface.

Carmeda^® BioActive Surface peer-reviewed published clinical and scientific findings:**

• Reduced risk of bleeding through maintenance of natural hemostatic mechanisms¹
• Reduced blood transfusion requirements^2,3
• Prevents coagulation cascade activation at Factor XIIa⁴
• This is earlier in the coagulation cascade than the production of thrombin
• Thrombin inactivation^5,6
• Maintains platelet function^7,8
• Reduced leukocytosis,⁹ granulocyte activation,^10,11,12 granular release by neutrophils^13,14
• Reduced complement activation^5,11,15,16
• Improved cost savings related to improved clinical outcomes.¹⁷

* Manufactured under license from Carmeda AB, Sweden. Carmeda is a registered trademark of Carmeda AB.

** Select published articles

Carmeda^® BioActive Surface is the industry standard in biosurface technology, with extensive published research documenting its benefits for thromboresistance and biocompatibility.